VCN-01 + gemcitabine + nab-paclitaxel

VCN-01 + gemcitabine + nab-paclitaxel is a combination therapy being developed primarily for **metastatic pancreatic ductal adenocarcinoma**. VCN-01 (also known as zabilugene almadenorepvec) is a systemically administered oncolytic adenovirus engineered to selectively replicate in tumor cells with a dysfunctional RB1 pathway and to express hyaluronidase, an enzyme that degrades the tumor stroma. This action facilitates both direct cytotoxicity (lysis of tumor cells) and enhances the penetration and efficacy of co-administered chemotherapies and possibly immunotherapy[1][3][5][7]. Nab-paclitaxel (marketed as Abraxane) is a nanoparticle albumin-bound formulation of paclitaxel, a microtubule inhibitor that disrupts cancer cell division. Gemcitabine (marketed as Gemzar) is a nucleoside analog that inhibits DNA synthesis, leading to apoptosis of rapidly dividing tumor cells[4][8]. This combination is administered intravenously and is being investigated in clinical trials (not approved) as frontline therapy for metastatic pancreatic cancer, showing improved efficacy and stromal penetration over chemotherapy alone[7].

Brand names

Abraxane

Other names

zabilugene almadenorepvecnab-paclitaxelnanoparticle albumin-bound paclitaxel